Solid Biosciences Shares Tick Up After FDA Clears Phase 3 Protocol for SGT-003
Shares of Solid Biosciences Inc. (NASDAQ:SLDB) climbed in early trading after the company said it has secured agreement with the U.S. Food and Drug Administration on the design of its Phase 3 IMPACT DUCHENNE trial for SGT-003. Solid plans to dose the first participant in the study in the first quarter of 2026 and will hold further meetings with the…